Constanta Timcheva

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

G. Bodoky, Constanta Timcheva, David R. Spigel et al. · Investigational New Drugs · 2011 · 230 citations

Medicine, Oncology, Pharmacology +13

Delays in diagnosis and treatment of breast cancer: a multinational analysis

Jacek Jassem, Vahit Özmen, Florin Bacanu et al. · European Journal of Public Health · 2013 · 148 citations · Full text

Medicine, Oncology, Breast Oncology +12

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC

Gilberto de Castro, Naiyer A. Rizvi, Peter Schmid et al. · Journal of Thoracic Oncology · 2022 · 72 citations · Full text

Medicine, Oncology, Pharmacology +17

Neutrophil to lymphocyte ratio as a potential predictive marker for treatment with pembrolizumab as a second line treatment in patients with non-small cell lung cancer

Mila Petrova, Mariyana Eneva, Jeliazko Arabadjiev et al. · BioScience Trends · 2020 · 56 citations · Full text

Medicine, Oncology, Pharmacology +16